Osmetech's thrombophilia risk test approved in US
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Osmetech's eSensor thrombophilia risk test. Thrombophilia causes an increased risk of blood clots in affected individuals, and can result from inherited defects in clotting factors. The multiplex test measures four genetic variants linked with thrombosis, in the genes for: factor V Leiden, factor II prothrombin, MTHFR 677 and MTHFR 1298. Osmetech (Pasadena, California) believes it is the only company to have received FDA clearance for all four markers. Roche Diagnostics already markets Factor V Leiden and Factor II (Prothrombin) G20210A test kits. Osmetech's test runs on its eSensor XT-8 system – the firm already has tests for warfarin and cystic fibrosis approved on this platform.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.